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Abstract
Heart transplantation is associated with rapid bone loss and an in-
creased prevalence and incidence of fractures. The aim of the present
study was to compare the bone mineral density (BMD) of 30 heart
transplant (HT) recipients to that of 31 chronic heart failure (CHF)
patients waiting for transplantation and to determine their biochemical
markers of bone resorption and hormone levels. The BMD of lumbar
spine and proximal femur was determined by dual-energy X-ray
absorptiometry. Anteroposterior and lateral radiographs of the tho-
racic and lumbar spine were also obtained. The mean age of the two
groups did not differ significantly. Mean time of transplantation was
25.4 – 21.1 months (6 to 88 months). Except for the albumin levels,
which were significantly higher, and magnesium levels, which were
significantly lower in HT patients when compared to CHF patients, all
other biochemical parameters and hormone levels were within the
normal range and similar in the two groups. Both groups had lower
BMD of the spine and proximal femur compared to young healthy
adults. However, the mean BMD of HT patients was significantly
lower than in CHF patients at all sites studied. Bone mass did not
correlate with time after transplantation or cumulative dose of
cyclosporine A. There was a negative correlation between BMD and
the cumulative dose of prednisone. These data suggest that bone loss
occurs in HT patients mainly due to the use of corticosteroids and that
in 30% of the patients it can be present before transplantation. It seems
that cyclosporine A may also play a role in this loss.
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Introduction
Organ transplantation became an impor-
tant field of medical practice after the advent
and availability of the immunosuppressive
drug cyclosporine A (1). Bone loss follow-
ing transplantation has been recently reported
(2-6); as a result, osteoporotic fractures can
seriously compromise the quality of life of
these patients. In contrast to transplantation
of other organs such as kidney or liver, bone
loss after heart transplantation (HT) is pre-
dominantly iatrogenic in view of the absence
of any other previous metabolic disorder
influencing bone metabolism in most pa-
tients (7). The impact of cyclosporine on
bone is still controversial (8,9). Cyclosporine
A induces high-turnover osteopenia in the
rat and may also contribute to bone loss after
heart transplantation (10,11). Prolonged im-
mobilization can explain bone loss but the
deleterious effect of glucocorticoid treatment
on bone is also likely to be an important
factor (7,12).
It has been observed that heart transplant
patients present the most rapid bone loss
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associated with fractures during the first year
post-transplantation (13,14). Sambrook et
al. (15) have suggested that bone loss post-
transplantation is due to a combination of
accelerated turnover and hypogonadism.
Thus, we investigated bone mass in heart
transplant and in chronic heart failure (CHF)
patients waiting for transplantation; further-
more, we evaluated the status and biochemi-
cal markers of bone resorption in these groups
of patients.
Patients and Methods
HT and CHF patients waiting for trans-
plantation and satisfying the eligibility crite-
ria were consecutively recruited from the
cardiology outpatient clinic at Escola Paulista
de Medicina, UNIFESP, from February 1994
to December 1995. Only ambulatory Cauca-
sian males older than 18 years were included
in the study. Only patients with more than
six months of transplantation were included
in the HT group. The etiology of the underly-
ing heart disease included ischemic (34.4%),
idiopathic congestive (34.4%), and Chagas
disease cardiomyopathy (24.6%).
Exclusion criteria were gastrointestinal,
liver, and kidney disease, kidney stones, dia-
betes, parathyroid or thyroid diseases, a veg-
etarian diet, present or past therapy, and
treatment with medications known to affect
bone metabolism (anticonvulsants, heparin,
vitamin D metabolites, calcium supplements,
aluminum-containing antacids). Sixty-six
patients were screened and 61 met the eligi-
bility criteria for this study, 30 for the HT
group and 31 for the CHF group. All of them
gave written informed consent to participate
in the study, which was approved by the
Ethics Committee of UNIFESP.
HT patients received initial and mainte-
nance immunosuppression with cyclospor-
ine, azathioprine, and prednisone. Steroids
were administered as follows: methylpred-
nisolone, 750-1000 mg for 3 days after sur-
gery. Oral prednisone (1.0 mg kg-1 day-1)
was administered in divided doses until day
7, reduced to 5-10 mg/day for 6 weeks, and
then withdrawn when possible. Ten patients
(33%) were taking no steroids at the time of
the study. Cyclosporine therapy was started
at the dose of 5 mg/kg orally on the fourth
day of transplantation. Target levels were
150 to 200 ng/ml during the early phase of
transplantation. Azathioprine was adminis-
tered as a single dose of 4 mg/kg before
surgery, and the maintenance dosage was 2
mg kg-1 day-1.
All patients were evaluated by the same
observer and answered a questionnaire elabo-
rated for this study.
Serum concentrations of total calcium,
phosphorus, alkaline phosphatase, creatinine,
albumin, and magnesium were measured by
automated techniques (Kodak Ektachem 750
XRT). Testosterone was measured by im-
munoradiometric assay. Follicle-stimulating
hormone (FSH) and luteinizing hormone
(LH) were measured by immunofluoromet-
ric assay. Serum intact parathyroid hormone
(PTH) concentration was measured by an
immunoradiometric assay (16).
The urinary collagen crosslinks pyridino-
line (Pyr) and deoxypyridinoline (D-Pyr)
were determined by high-performance liq-
uid chromatography and identified by
spectrofluorimetry according to a modifica-
tion of the method described by Black et al.
(17) and Uebelhart et al. (18). The Pyr and
D-Pyr values were determined by compari-
son with an external standard and corrected
for creatinine excretion. The data are re-
ported as pmol per µmol creatinine.
A standard set of anteroposterior and
lateral radiographs of the thoracic and lum-
bar spine was obtained. Vertebral fracture
was defined as the radiographic presence of
a 20% or more anterior height reduction
relative to the posterior height (19). The
number of vertebral fractures was deter-
mined. The history of fractures at other sites
was recorded, and X-rays were taken only
when there was any doubt. All X-rays were
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evaluated by an examiner blind to the patient
group.
Bone mineral density (BMD) of the lum-
bar spine and right proximal femur was meas-
ured by dual-energy X-ray absorptiometry
utilizing a DPX Bone Densitometer (Lunar,
Inc., Madison, WI). The in vivo coefficient
of variation is 1.2% for the lumbar spine
(L2-L4) and 2.0% for the femoral neck. Meas-
urements of BMD, reported as g/cm2, were
compared with those of young adults and
age- and sex-matched normal subjects de-
rived from the range indicated by the manu-
facturer. Standardized analyses were also
used to compare individual BMD determi-
nations to those of young adults (T-score)
and age-matched (Z-score) controls. Only
lumbar vertebrae radiographically shown to
be intact were included in the bone density
analysis. We also excluded patients with air
artifacts on or around the major trochanter
from analysis.
Statistical analysis was performed using
the unpaired Student t-test and Mann-
Whitney test. The Spearman rank correla-
tion test was used to correlate time after
transplantation, duration of CHF, cumula-
tive doses of prednisone and cyclosporine-A
with bone mass. Results are reported as means
– SD. A P less than 0.05 was considered to
be statistically significant.
Results
The clinical characteristics of the pa-
tients are shown in Table 1. The mean age of
HT patients (48.6 – 10.8 years) was similar
to that of CHF patients (43.5 – 10.5 years),
as also was height (168.3 – 4.5 vs 166.7 – 8.0
cm, respectively). The weight and body mass
index of HT patients were significantly higher
than those of CHF subjects (76.2 – 10.7 vs
62.2 – 11.5 kg, P<0.001; 26.8 – 3.3 vs 22.3 –
3.6 kg/m2, P<0.001, respectively). Mean time
after heart transplantation at the time of in-
clusion in the study was 25.4 – 21.1 months
(range: 6 to 88 months).
Biochemical parameters
Serum calcium, phosphorus, alkaline
phosphatase, creatinine, testosterone, PTH,
FSH, LH, and urinary Pyr and D-Pyr excre-
tion were normal for all patients and not
significantly different between the two
groups, although there was a trend to higher
creatinine levels in the HT group. Albumin
levels were significantly higher and magne-
sium levels were significantly lower in HT
patients compared to CHF patients. The re-
sults of these biochemical determinations
are summarized in Table 2.
Table 2 - Biochemical parameters and hormonal determinations for heart transplant
(HT) and chronic heart failure (CHF) patients.
Data are reported as means ± SD. *P<0.001 versus HT. **P<0.008 versus HT (Mann-
Whitney and Student t-test).
HT N CHF N Normal
values
Calcium (mg/dl) 9.6 ± 0.6 29 9.4 ± 0.9 17 8.5 - 10.5
Phosphorus (mg/dl) 3.3 ± 0.5 28 3.6 ± 0.8 12 2.5 - 4.5
Alkaline phosphatase (U/l) 115 ± 40 30 139 ± 69 29 50 - 180
Magnesium (mg/dl) 1.6 ± 0.3 30 2.1 ± 0.3* 26 1.7 - 2.2
Creatinine (mg/dl) 1.3 ± 0.4 30 1.1 ± 0.4 29 0.6 - 1.4
Albumin (g/dl) 4.0 ± 0.4 30 3.6 ± 0.7** 28 3.2 - 5.6
Total testosterone (ng/dl) 447 ± 146 17 637 ± 360 12 350 - 900
FSH (IU/l) 2.0 ± 1.4 11 2.6 ± 2.1 6 1.0 - 12.0
LH (IU/l) 4.6 ± 2.3 21 4.5 ± 4.7 9 1.0 - 10.0
Intact PTH (pg/ml) 65.0 ± 35.5 23 54.3 ± 68.2 9 4 - 70
Pyridinoline 44.7 ± 26.0 19 43.4 ± 19.8 14 11 - 77
(pmol/µmol creatinine)
Deoxypyridinoline 4.4 ± 2.1 19 2.8 ± 1.7 14 0.6 - 6.3
(pmol/µmol creatinine)
Table 1 - Clinical characteristics of heart transplant (HT) recipients and chronic heart
failure (CHF) patients.
Data are reported as means ± SD. BMI, Body mass index. *P<0.001 versus HT (Mann-
Whitney and Student t-test).
HT (N = 30) CHF (N = 31)
Age (years) 48.6 ± 10.8 43.5 ± 10.5
Weight (kg) 76.2 ± 10.7 62.2 ± 11.5*
Height (cm) 168.3 ± 4.5 166.7 ± 8.0
BMI (kg/m2) 26.8 ± 3.3 22.3 ± 3.6*
Duration of CHF (months) - 18.0 ± 21.1
Time after transplantation (months) 25.4 ± 21.1 -
Cumulative prednisone dosage (g) 11.2 ± 6.0 -
Cumulative cyclosporine A dosage (g) 227.7 ± 191.0 -
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Bone densitometry
The bone density determinations of the
lumbar spine and proximal femur are shown
in Table 3.
T-scores for the lumbar spine and proxi-
mal femur were below normal levels in HT
patients and around -1.0 in CHF patients.
The mean BMD of HT patients was signifi-
cantly lower than in CHF patients at all sites.
When the BMD of both groups was com-
pared to that of age-matched controls, CHF
patients could be considered normal since
their Z-scores at all sites were between -0.18
and -0.48, while the Z-scores of HT patients
remained below -1.0 at all sites.
Bone mass did not correlate with time
after transplantation (rs = -0.31, NS in the
lumbar spine; rs = -0.31, NS in the femoral
neck; rs = -0.28, NS in the trochanter) or
cumulative dosage of cyclosporine (rs =
-0.31, NS for the lumbar spine; rs = -0.24,
NS for the femoral neck; rs = -0.20, NS for
the trochanter). In the CHF group, bone mass
did not correlate with duration of congestive
heart failure (rs = -0.18, NS for the lumbar
spine; rs = 0.07, NS for the femoral neck; rs
= 0.01, NS for the trochanter). There was a
negative correlation between BMD at all
sites and cumulative dose of prednisone (r =
-0.53, P<0.003 for the lumbar spine; r =
-0.37, P<0.05 for the femoral neck; r = -0.36,
P<0.05 for the trochanter). We did not ob-
serve significant differences between HT
patients taking corticosteroids and patients
who were not on corticotherapy at the time
of the study.
Vertebral fractures
Vertebral fractures were observed in 15
(50%) of HT patients and in four (16%) of 25
radiographs of CHF patients examined. In 5
patients awaiting transplants, it was not pos-
sible to obtain radiographs. Lumbar BMD
did not differ significantly between those
with and those without vertebral fractures,
although the average lumbar BMD and lum-
bar Z-score tended to be lower among HT
patients with vertebral fractures. HT patients
with vertebral fractures were significantly
older than those without fractures. The T6
and T7 thoracic vertebrae were the most
frequently fractured in HT patients (G =
25.47, P<0.05). No laboratory parameters,
including PTH, Pyr, and D-Pyr, differed be-
tween patients with and without fractures.
CHF patients with and without fractures pre-
sented similar results for all laboratory pa-
rameters analyzed.
Discussion
These data suggest that patients who un-
derwent heart transplantation have an addi-
tional bone loss in the spine and proximal
femur when compared to CHF patients. When
compared to patients awaiting transplant,
Table 3 - Bone mineral density (BMD) of heart transplant (HT) and chronic heart failure (CHF) patients.
Data are reported as means ± SD. BMD, Bone mineral density. *P<0.05 versus CHF patients. **P<0.007
versus CHF patients. +P<0.004 versus CHF patients (Mann-Whitney test).
Lumbar spine Femoral neck Trochanter
HT CHF HT CHF HT CHF
No. of patients 29 29 30 31 29 26
BMD (g/cm2) 1.04 ± 0.14* 1.12 ± 0.16 0.86 ± 0.14* 0.95 ± 0.16 0.75 ± 0.11* 0.82 ± 0.12
T Score -1.70 ± 1.19* -0.98 ± 1.37 -1.71 ± 1.18* -0.98 ± 1.32 -1.67 ± 1.04* -1.01 ± 1.11
Z Score -1.26 ± 1.15** -0.29 ± 1.23 -1.08 ± 0.97+ -0.18 ± 1.20 -1.41 ± 0.93+ -0.48 ± 1.12
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the BMD of HT patients was 7.5% lower in
the spine and 8.9% lower in the femoral neck
and trochanter.
The pathogenic mechanisms leading to
osteoporosis after heart transplantation are
not well understood. Known or suspected
risk factors for osteoporosis including nega-
tive calcium balance, physical inactivity, di-
etary calcium deficiency, exposure to to-
bacco and/or alcohol, and therapy with loop
diuretics are often present. Lower testoster-
one levels could be another reason for
osteopenia in HT patients receiving cyclo-
sporine treatment (20). Osteopenia may be
present prior to cardiac transplantation. Our
data suggest that CHF patients have bone
loss, since they have T-scores around -1.0.
However, comparing them to age-matched
controls, we found reduced bone mass only
in 30% of patients, and their mean Z-score
was around -0.3. Shane et al. (21), studying
101 patients with severe CHF, observed
osteopenia or osteoporosis in approximately
half of the patients, and concluded that evi-
dence of increased bone resorption was as-
sociated with abnormal concentrations of
calciotropic hormones and with the severity
of CHF.
Our study demonstrated that skeletal
osteopenia is present in a significant propor-
tion of patients submitted to heart transplan-
tation. Other authors, using similar tech-
niques to measure bone density, also found
bone loss in the spine and proximal femur
(14,22-24). In contrast, Lee et al. (25) re-
ported bone loss only in the femoral neck in
both transplanted and pre-transplanted pa-
tients, with no significant difference between
them.
Fifty percent of patients who had under-
gone transplants showed radiological evi-
dence of one or more compression fractures,
compared to 16% of CHF patients who were
awaiting transplantation. Mean vertebral
bone density was not significantly different
between the two groups. Although we found
a negative correlation between BMD and
cumulative doses of prednisone, we did not
find that HT patients with fractures used
higher doses of this drug or of cyclosporine
than patients with no fractures. Of all other
variables analyzed, only mean age of frac-
tured patients was significantly higher. These
results differ from those obtained by
Muchmore et al. (5), who found that al-
though there was much variation in the val-
ues of BMD that were obtained, almost all of
their HT patients lost vertebral BMD after
transplantation; however, none of their pa-
tients had vertebral compression fractures.
The basis for the increased proportion of
transplanted patients with vertebral compres-
sion fractures compared to patients awaiting
transplant is unclear. Except for the cumula-
tive dose of corticosteroid, no other clinical
parameters predicted BMD, including time
since transplantation, cumulative dose of
cyclosporine, or duration of congestive heart
failure.
Some factors can be related to bone loss
after cardiac transplantation. Sambrook et
al. (15) suggested that bone loss after cardiac
transplantation is related to hypogonadism
due to the initial high doses of corticoste-
roids that these patients receive immediately
after surgery. These authors observed de-
creased serum levels of testosterone imme-
diately after surgery. In the present study,
testosterone, LH, and FSH levels were not
significantly different between groups. The
difference between our results and those
reported in Sambrooks study may have been
due to the small number of patients in this
study for whom it was possible to measure
these hormones, since there was a trend to
lower serum testosterone levels in HT pa-
tients (447 vs 637 mg/dl).
All serum laboratory measurements were
normal and not significantly different be-
tween the two groups, except for magnesium
and albumin. Serum albumin levels were
significantly higher in HT patients. This re-
sult was expected. Higher serum albumin
levels in HT patients could reflect better
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ingestion of proteins and resolution of car-
diac cachexia. On this basis, higher bone
mass might be expected for HT patients, but
this was not the case. On the other hand,
higher serum albumin levels in HT patients
might indicate an excessive ingestion of pro-
teins, determining a negative balance of cal-
cium and bone loss (26). We do not believe,
however, that the ingested protein played a
substantial role in the decreased bone den-
sity found in HT patients.
We found lower magnesium levels in HT
patients compared to CHF patients. This was
not expected, since we believed that CHF
patients would also have low magnesium
levels due to diuretic-induced renal loss.
Cyclosporine use may justify the lower mag-
nesium levels in HT patients due to the greater
renal excretion that occurs with the use of
this drug (1,27).
Magnesium may affect bone resorption.
Johannesson and Raisz (28) reported lower
resorption in response to PTH and
1,25(OH)2D3 in magnesium-deficient bone.
Hypomagnesemia was associated with lower
PTH synthesis and secretion (29-31) and
with altered target organ responsiveness to
PTH action (30). Mg supplementation for 2
years significantly increased BMD in pa-
tients with osteoporosis associated with glu-
ten-sensitive enteropathy (32).
Hypomagnesemia associated with low
bone mass in HT patients has never been
suggested before. Shane et al. (33) found
normal magnesium levels in transplanted
recipients. Other studies are needed to deter-
mine the importance of this factor in heart
transplantation.
Pyr and D-Pyr were similar in both groups.
These are well-known parameters of bone
resorption. Other authors observed higher
levels of bone resorption markers and de-
creases in serum testosterone and osteocal-
cin immediately after transplantation (14,24).
Sambrook et al. (15) even suggested that
osteocalcin could be used as a predictive
measurement of bone loss in these patients.
Although urinary crosslink excretion was
not elevated, serum osteocalcin and bone-
specific alkaline phosphatase were not meas-
ured, and these parameters might be helpful
in order to determine whether or not cyclo-
sporine or corticosteroid had any significant
influence on bone turnover and the osteoporo-
sis detected in patients submitted to heart
transplantation.
Osteoporosis is a frequent complication
of therapy with glucocorticoids, and it was
not a surprise that the cumulative dose of
prednisone was negatively correlated with
BMD. Corticosteroid-induced osteoporosis
is characterized by a disproportionate loss of
trabecular bone relative to cortical bone (34),
which explains extensive early observations
showing that the spine is the major site of
pathologic fracture and radiographic disease.
The action of cyclosporine on bone is
controversial. It has been postulated to cause
bone loss in transplant recipients (7). In vitro
studies have demonstrated that cyclosporine
decreases bone resorption (35-37), while in
vivo experiments on rats have resulted in
severe high-turnover osteopenia without any
changes in ionized calcium, phosphate, or
PTH levels (10-11,38).
The combined action of cyclosporine and
prednisone on human bone has not been well
established. When HT patients treated with
this therapeutic scheme were compared to
patients with immunologic diseases treated
only with prednisone, osteocalcin levels were
found to be significantly higher in patients
who received both drugs (39). However, it is
possible that cyclosporine decreases the in-
hibitory action of glucocorticoids on bone
formation, leading to an accelerated bone
formation state. In vivo experiments in rats
have demonstrated that the combined use of
glucocorticoids and cyclosporine minimized
the adverse bone effects of either agent alone
(40). We did not consider the cumulative
dose of cyclosporine to predict BMD or
incidence of vertebral fractures in our pa-
tients.
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It seems to us that cyclosporine interferes
with the corticosteroid action on bone, chang-
ing the loss due to decreased bone formation
characteristic of corticosteroid-induced os-
teoporosis to a high-turnover bone state, with
high bone formation and resorption. Thus,
the pathogenesis of osteoporosis in these
patients is considerably different from that
described for patients using only corticoste-
roids.
Prevention and treatment of bone loss in
transplant recipients may be as important as
the control of any other possible symptoms
that may be observed in this population.
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